The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Official Title: An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated
Study ID: NCT01137006
Brief Summary: A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
ImClone Investigational Site, Boston, Massachusetts, United States
ImClone Investigational Site, New York, New York, United States
Name: E-mail: ClinicalTrials@ ImClone.com
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR